Blog

  • Cobo Turns Nine: Nine Years, Nine Stories

    Nine Years of Building Trusted Infrastructure for Wallets and Payments, for Humans and AI Agents

    SINGAPORE, October 14, 2026 – Cobo, a trusted digital asset infrastructure company, today marks its ninth anniversary with “9 Stories,” a series of short films featuring founders, clients, partners, and team members sharing their experiences and perspectives in their own words. After nine years of delivering Wallet-as-a-Service (WaaS) and multi-chain solutions, Cobo has served more than 680 clients across nearly 50 countries and regions.

    Founded in 2017 by blockchain pioneers Discus Fish and Dr. Changhao Jiang, Cobo has built trusted infrastructure with a focus on operational efficiency and risk management.

    “What I hope never changes is our commitment to prioritizing long-term value over short-term trends, and making decisions about what to build based on what creates real value for our users,” said Dr. Changhao Jiang, Co-founder & CTO.

    That philosophy continues to guide Cobo as it responds to emerging shifts in how digital assets are used and managed. In 2026, AI tools are enabling organizations to automate complex workflows and reduce reliance on traditional software while creating demand for secure, enforceable ways for AI agents to hold assets, execute payments, and manage treasury on-chain.

    Cobo’s response is the Cobo Agentic Wallet (CAW), launched earlier this year as a non-custodial-by-default, MPC-secured wallet purpose-built for AI agents. It allows autonomous on-chain operations within human-defined boundaries enforced at the infrastructure level.

    “To our clients: thank you for trusting Cobo and giving us the room to keep iterating. I believe a better future, perhaps beyond what we can imagine today, lies ahead, and we look forward to building it together,” said Discus Fish, Co-founder & CEO.

    As it marks its ninth anniversary, Cobo looks back on key milestones, including a $13 million Series A in 2018, a $40 million Series B+ led by DST Global, IMO Ventures, and A&T Capital in 2021, the launch of WaaS, SOC 2 Type II (Big Four audited), and ISO 27001 certification.

    New stories from the “9 Stories” series will be released over the coming weeks starting today. Watch them at https://www.cobo.com/9th.

    About Cobo

    Founded in 2017 and headquartered in Singapore, Cobo builds trusted infrastructure for wallets and payments, for humans and AI agents, with licensed entities in Hong Kong, Canada, and the United States. Cobo is SOC 2 Type II (Big Four audited) and ISO 27001 certified, and has secured billions in client assets with zero security incidents since 2017.

    Visit https://www.cobo.com for more information.

  • FX Junction Brings Copy Trading to Everyone, While Their Money Never Leaves With Their Broker

    Fomboni, Comoros, October 14th, 2026, FinanceWire

    Investors In 50+ Countries Can Now Follow Verified Traders Automatically, Through The Mt4, Mt5 Or Dxtrade Account They Already Own

    FX Junction, the social and copy trading platform, is making professional-grade trading strategies accessible to anyone with a brokerage account. Investors connect their existing MetaTrader 4, MetaTrader 5 or DXtrade account, choose from a roster of verified signal providers, and see those providers’ trades mirrored in their own account in real time. The model rests on one simple promise: FX Junction never holds client money. Every dollar stays with the investor’s own broker, under the investor’s own control.

    Trading Stops Being A Solitary Pursuit

    For years, retail trading has meant one person alone with a screen full of charts. FX Junction is built on the opposite idea. Its global community connects beginners and seasoned professionals, young and old, so that strategies, insight and experience can be shared across borders. A newcomer no longer has to learn everything the hard way; they can follow traders whose full record is public.

    Up and running in four steps

    • Create an account. Registration takes minutes and requires no prior trading experience.
    • Connect an existing account. Investors link an MT4, MT5 or DXtrade account from virtually any major broker.
    • Choose whom to follow. Each signal provider has a verified performance history, with detailed analytics covering more than five years of data.
    • Let the platform do the work. Trades are replicated automatically, with latency the company puts below 0.1 seconds.

    Built For Control, Not Blind Faith

    FX Junction gives investors the tools to decide how much risk they take on. Position sizing, stop-loss settings and AI-assisted risk controls sit alongside 24/7 portfolio monitoring, live notifications and full reporting. Users can copy several traders at once across Forex, stocks, indices and commodities, more than 150 instruments in total, building a diversified portfolio from a single dashboard.

    Because funds never move to FX Junction, investors keep the broker relationship they already trust. They can trade independently alongside their copied positions at any time.

    More Than A Copy Button

    FX Junction pairs automation with education and research. Its free Education Hub offers short courses on signal-provider analytics, the psychology of copying, and portfolio architecture. Daily market news, live technical analysis with entry, stop-loss and take-profit levels, and monthly model equity portfolios keep members informed. The October 2026 portfolio, for example, focuses on ten companies in nuclear generation, grid equipment and data-center power, the infrastructure behind surging AI electricity demand.

    For investors who want a guiding hand, FX Junction offers annual support packages from $199 to $1,999 per year. Every tier includes MetaTrader and DXtrade training, performance-based guidance on signal providers, portfolio and diversification consultation, and risk and money management. Higher tiers add technical and fundamental analysis training, company results briefings and alerts when the investment outlook changes.

    Experienced traders can also join the other side of the platform as signal providers, while businesses can work with FX Junction through API, white-label and referral programs.

    About FX Junction

    FX Junction is a social and copy trading platform that lets investors automatically replicate the trades of verified signal providers in their own MT4, MT5 or DXtrade accounts. Available in more than 50 countries and compatible with over 1,000 brokers, it combines automated copying with risk controls, market research and education, while client funds remain at the investor’s own broker. FX Junction is operated by FXJ LTD, Bonovo Road, P.B. 1257, Fomboni, Island of Mohéli, Comoros Union.

    Learn more at fxjunction.com.

    Risk warning: Trading leveraged products carries a high level of risk and may not be suitable for all investors. Past performance is no guide to future results, and investors may get back less than they invested. FX Junction does not provide investment advice. Company figures cited are as reported on fxjunction.com as of October 12, 2026.

    Contact

    Team of analysts
    support@fxjunction.com

  • FX Junction Brings Copy Trading to Everyone, While Their Money Never Leaves With Their Broker

    Fomboni, Comoros, October 14th, 2026, FinanceWire

    Investors In 50+ Countries Can Now Follow Verified Traders Automatically, Through The Mt4, Mt5 Or Dxtrade Account They Already Own

    FX Junction, the social and copy trading platform, is making professional-grade trading strategies accessible to anyone with a brokerage account. Investors connect their existing MetaTrader 4, MetaTrader 5 or DXtrade account, choose from a roster of verified signal providers, and see those providers’ trades mirrored in their own account in real time. The model rests on one simple promise: FX Junction never holds client money. Every dollar stays with the investor’s own broker, under the investor’s own control.

    Trading Stops Being A Solitary Pursuit

    For years, retail trading has meant one person alone with a screen full of charts. FX Junction is built on the opposite idea. Its global community connects beginners and seasoned professionals, young and old, so that strategies, insight and experience can be shared across borders. A newcomer no longer has to learn everything the hard way; they can follow traders whose full record is public.

    Up and running in four steps

    • Create an account. Registration takes minutes and requires no prior trading experience.
    • Connect an existing account. Investors link an MT4, MT5 or DXtrade account from virtually any major broker.
    • Choose whom to follow. Each signal provider has a verified performance history, with detailed analytics covering more than five years of data.
    • Let the platform do the work. Trades are replicated automatically, with latency the company puts below 0.1 seconds.

    Built For Control, Not Blind Faith

    FX Junction gives investors the tools to decide how much risk they take on. Position sizing, stop-loss settings and AI-assisted risk controls sit alongside 24/7 portfolio monitoring, live notifications and full reporting. Users can copy several traders at once across Forex, stocks, indices and commodities, more than 150 instruments in total, building a diversified portfolio from a single dashboard.

    Because funds never move to FX Junction, investors keep the broker relationship they already trust. They can trade independently alongside their copied positions at any time.

    More Than A Copy Button

    FX Junction pairs automation with education and research. Its free Education Hub offers short courses on signal-provider analytics, the psychology of copying, and portfolio architecture. Daily market news, live technical analysis with entry, stop-loss and take-profit levels, and monthly model equity portfolios keep members informed. The October 2026 portfolio, for example, focuses on ten companies in nuclear generation, grid equipment and data-center power, the infrastructure behind surging AI electricity demand.

    For investors who want a guiding hand, FX Junction offers annual support packages from $199 to $1,999 per year. Every tier includes MetaTrader and DXtrade training, performance-based guidance on signal providers, portfolio and diversification consultation, and risk and money management. Higher tiers add technical and fundamental analysis training, company results briefings and alerts when the investment outlook changes.

    Experienced traders can also join the other side of the platform as signal providers, while businesses can work with FX Junction through API, white-label and referral programs.

    About FX Junction

    FX Junction is a social and copy trading platform that lets investors automatically replicate the trades of verified signal providers in their own MT4, MT5 or DXtrade accounts. Available in more than 50 countries and compatible with over 1,000 brokers, it combines automated copying with risk controls, market research and education, while client funds remain at the investor’s own broker. FX Junction is operated by FXJ LTD, Bonovo Road, P.B. 1257, Fomboni, Island of Mohéli, Comoros Union.

    Learn more at fxjunction.com.

    Risk warning: Trading leveraged products carries a high level of risk and may not be suitable for all investors. Past performance is no guide to future results, and investors may get back less than they invested. FX Junction does not provide investment advice. Company figures cited are as reported on fxjunction.com as of October 12, 2026.

    Contact

    Team of analysts
    support@fxjunction.com

  • INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro

    Boca Raton, Florida, October 14th, 2026, FinanceWire

    • Collaboration combines INmune Bio’s clinical research with QCi’s Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
    • Initial engagement marks QCi’s first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

    INmune Bio Inc. (Nasdaq: INMB) and Quantum Computing Inc. (Nasdaq: QUBT) today announced a collaboration to apply quantum computing, artificial intelligence (AI) and data analytics to identify new potential applications for XPro (XPro1595), INmune Bio’s investigational treatment for Alzheimer’s disease and other disease conditions.

    The collaboration brings together INmune Bio’s data from pre-clinical research through four clinical trials and understanding of disease biology with QCi’s Dirac-3S quantum optimization machine. Working with clinical and publicly available biomedical datasets, the companies intend to use quantum computing alongside AI and conventional data analytics to uncover relationships that could help find diseases driven by the same biology XPro targets, and to prioritize those with the greatest potential for success.

    The Stage 1 engagement represents QCi’s first commercial customer in the pharmaceutical and biotechnology market. The agreement also provides options for additional work as INmune Bio advances its clinical development programs.

    “We’ve built a large clinical dataset on Alzheimer’s and other diseases, backed by years of work with XPro,” said David Moss, Chief Executive Officer of INmune Bio. “This collaboration allows us to examine patient populations and biomarkers most likely to predict responses by analyzing large data sets. We’ll look for the diseases with the greatest potential for success, those whose human biology matches what we’ve already seen XPro do, starting with rare diseases where trials can be smaller, faster and more capital-efficient, and where qualifying pediatric approvals may earn a Priority Review Voucher.”

    Together, the companies will build on INmune Bio’s research into XPro to explore where its approach to targeting inflammation may offer the greatest potential. XPro is designed to selectively inhibit soluble tumor necrosis factor (TNF), a protein involved in inflammation, while preserving other TNF functions important to the immune system. INmune Bio is investigating its potential in neurological and rare diseases where this targeted approach may offer a therapeutic benefit.

    Using its Dirac-3S entropy quantum optimization machine alongside AI and conventional analytics, QCi will look for patterns and relationships across these datasets that could help researchers better understand treatment responses, identify promising patient populations and prioritize new indications for further study.

    “This is a great example of what practical quantum computing can look like today,” said Yuping Huang, Chairman and Chief Executive Officer of QCi. “INmune Bio has a complex scientific problem and a substantial body of clinical and biological data. Our job is to bring new computing capabilities to that problem and see what we can learn. The potential to help researchers make better decisions about future treatments is exciting, and it opens an important new market for QCi.”

    An important part of the program will be testing where quantum optimization adds value. The companies plan to compare results from QCi’s quantum optimization machine with appropriate conventional statistical and machine-learning methods, evaluating which approaches are best suited to different parts of the analysis.

    The work is also intended to establish a repeatable discovery process through quantum computing that INmune Bio can use with additional datasets and potential disease indications.

    For INmune Bio, the collaboration offers a new way to evaluate the broader potential of XPro and prioritize future development opportunities. For QCi, it represents an opportunity to showcase how its room-temperature, low-power quantum computing technology can be applied to complex, real-world problems in pharmaceutical research.

    About INmune Bio Inc.

    INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.

    INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:

    • CORDStrom™: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.
    • XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform designed to selectively neutralize soluble TNF (sTNF) and reduce neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.

    To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

    About Quantum Computing Inc.

    Quantum Computing Inc. (Nasdaq: QUBT) is an integrated quantum photonics company developing and manufacturing technologies that use light to compute complex information, capture hard-to-detect signals and communicate more securely. QCi brings together quantum optics, integrated photonics, semiconductor manufacturing and advanced packaging to create a more direct path from advanced science to practical products.

    QCi’s portfolio includes quantum machines, photonic chips, components, modules and subsystems, as well as foundry and advanced manufacturing services. Its technologies are designed to operate at room temperature and low power, without the specialized cooling infrastructure required by many quantum approaches. These advantages enable deployment across computing and AI, secure communications, sensing and imaging, aerospace and defense, and other demanding applications.

    Headquartered in Hoboken, New Jersey, QCi has operations across the United States. By combining advanced physics, device engineering and scalable manufacturing, QCi is working to make quantum and advanced photonic technologies more accessible and useful in the real world.

    To learn more about QCi and its approach to harnessing light for practical quantum computing, please visit www.quantumcomputinginc.com.

    Forward Looking Statements:

    InMune Bio Inc.

    The Company’s product candidates remain in clinical development stage and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including Ebstrocel™, XPro™ and INKmune™ trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™, XPro1595™ (XPro™, pegipanermin), and INKmune™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

    Quantum Computing Inc.

    This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements and forecasts, generally identified by terms such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “enhance,” “intends,” “goal,” “objective,” “seek,” “attempt,” “aim to,” or variations of these or similar words, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief, or current expectations of QCi and members of its management as well as the assumptions on which such statements are based. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including QCi’s ability to use quantum optimization to analyze biomedical data, whether collaboration will generate relevant and valuable insights, the performance of the Dirac-3S in the intended application, the ability of quantum optimization to contribute to the development of new treatments, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, QCi undertakes no obligation to update or revise forward- looking statements to reflect changed conditions.

    Contacts

    Head of Investor Relations
    Daniel Carlson
    dcarlson@inmunebio.com
    Head of Investor Relations
    David Moskowtiz
    investors@quantumcomputinginc.com

  • INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro

    Boca Raton, Florida, October 14th, 2026, FinanceWire

    • Collaboration combines INmune Bio’s clinical research with QCi’s Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
    • Initial engagement marks QCi’s first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

    INmune Bio Inc. (Nasdaq: INMB) and Quantum Computing Inc. (Nasdaq: QUBT) today announced a collaboration to apply quantum computing, artificial intelligence (AI) and data analytics to identify new potential applications for XPro (XPro1595), INmune Bio’s investigational treatment for Alzheimer’s disease and other disease conditions.

    The collaboration brings together INmune Bio’s data from pre-clinical research through four clinical trials and understanding of disease biology with QCi’s Dirac-3S quantum optimization machine. Working with clinical and publicly available biomedical datasets, the companies intend to use quantum computing alongside AI and conventional data analytics to uncover relationships that could help find diseases driven by the same biology XPro targets, and to prioritize those with the greatest potential for success.

    The Stage 1 engagement represents QCi’s first commercial customer in the pharmaceutical and biotechnology market. The agreement also provides options for additional work as INmune Bio advances its clinical development programs.

    “We’ve built a large clinical dataset on Alzheimer’s and other diseases, backed by years of work with XPro,” said David Moss, Chief Executive Officer of INmune Bio. “This collaboration allows us to examine patient populations and biomarkers most likely to predict responses by analyzing large data sets. We’ll look for the diseases with the greatest potential for success, those whose human biology matches what we’ve already seen XPro do, starting with rare diseases where trials can be smaller, faster and more capital-efficient, and where qualifying pediatric approvals may earn a Priority Review Voucher.”

    Together, the companies will build on INmune Bio’s research into XPro to explore where its approach to targeting inflammation may offer the greatest potential. XPro is designed to selectively inhibit soluble tumor necrosis factor (TNF), a protein involved in inflammation, while preserving other TNF functions important to the immune system. INmune Bio is investigating its potential in neurological and rare diseases where this targeted approach may offer a therapeutic benefit.

    Using its Dirac-3S entropy quantum optimization machine alongside AI and conventional analytics, QCi will look for patterns and relationships across these datasets that could help researchers better understand treatment responses, identify promising patient populations and prioritize new indications for further study.

    “This is a great example of what practical quantum computing can look like today,” said Yuping Huang, Chairman and Chief Executive Officer of QCi. “INmune Bio has a complex scientific problem and a substantial body of clinical and biological data. Our job is to bring new computing capabilities to that problem and see what we can learn. The potential to help researchers make better decisions about future treatments is exciting, and it opens an important new market for QCi.”

    An important part of the program will be testing where quantum optimization adds value. The companies plan to compare results from QCi’s quantum optimization machine with appropriate conventional statistical and machine-learning methods, evaluating which approaches are best suited to different parts of the analysis.

    The work is also intended to establish a repeatable discovery process through quantum computing that INmune Bio can use with additional datasets and potential disease indications.

    For INmune Bio, the collaboration offers a new way to evaluate the broader potential of XPro and prioritize future development opportunities. For QCi, it represents an opportunity to showcase how its room-temperature, low-power quantum computing technology can be applied to complex, real-world problems in pharmaceutical research.

    About INmune Bio Inc.

    INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.

    INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:

    • CORDStrom™: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.
    • XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform designed to selectively neutralize soluble TNF (sTNF) and reduce neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.

    To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

    About Quantum Computing Inc.

    Quantum Computing Inc. (Nasdaq: QUBT) is an integrated quantum photonics company developing and manufacturing technologies that use light to compute complex information, capture hard-to-detect signals and communicate more securely. QCi brings together quantum optics, integrated photonics, semiconductor manufacturing and advanced packaging to create a more direct path from advanced science to practical products.

    QCi’s portfolio includes quantum machines, photonic chips, components, modules and subsystems, as well as foundry and advanced manufacturing services. Its technologies are designed to operate at room temperature and low power, without the specialized cooling infrastructure required by many quantum approaches. These advantages enable deployment across computing and AI, secure communications, sensing and imaging, aerospace and defense, and other demanding applications.

    Headquartered in Hoboken, New Jersey, QCi has operations across the United States. By combining advanced physics, device engineering and scalable manufacturing, QCi is working to make quantum and advanced photonic technologies more accessible and useful in the real world.

    To learn more about QCi and its approach to harnessing light for practical quantum computing, please visit www.quantumcomputinginc.com.

    Forward Looking Statements:

    InMune Bio Inc.

    The Company’s product candidates remain in clinical development stage and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including Ebstrocel™, XPro™ and INKmune™ trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™, XPro1595™ (XPro™, pegipanermin), and INKmune™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

    Quantum Computing Inc.

    This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements and forecasts, generally identified by terms such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “enhance,” “intends,” “goal,” “objective,” “seek,” “attempt,” “aim to,” or variations of these or similar words, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief, or current expectations of QCi and members of its management as well as the assumptions on which such statements are based. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including QCi’s ability to use quantum optimization to analyze biomedical data, whether collaboration will generate relevant and valuable insights, the performance of the Dirac-3S in the intended application, the ability of quantum optimization to contribute to the development of new treatments, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, QCi undertakes no obligation to update or revise forward- looking statements to reflect changed conditions.

    Contacts

    Head of Investor Relations
    Daniel Carlson
    dcarlson@inmunebio.com
    Head of Investor Relations
    David Moskowtiz
    investors@quantumcomputinginc.com

  • Evolution Metals & Technologies Corp. Reaffirms $400 Million to $460 Million FY2027 Revenue Guidance, Unveils Eight Sintered Magnet Grades Covering an Estimated 75% of Global NdFeB Revenue, and Moves to Answer U.S. Army Call for Rare Earth Magnets

    Miami, Florida, October 14th, 2026, FinanceWire

    Seven of eight grades customer-certified and first 13 of 57 containers of ULVAC equipment landed in Pohang on the path to more than 10,000 metric tons of annual capacity; SmCo production equipment targeted for mid-2027 as DFARS 252.225-7052 extends its mine-to-magnet restriction to SmCo magnets on January 1, 2027

    Evolution Metals & Technologies Corp. (“EM&T” or the “Company”) (Nasdaq: EMAT), a U.S.-based critical materials and advanced manufacturing company, today announced that its portfolio of eight sintered neodymium-iron-boron (“NdFeB”) rare earth magnet grades represents what the Company estimates to be approximately 75% of global sintered NdFeB magnet revenue and approximately 52% of global volume — placing EM&T squarely at the commercial center of the rare earth magnet market. The Company also reaffirmed its fiscal 2027 revenue guidance of $400 million to $460 million, announced that it expects to begin acquiring equipment to produce samarium cobalt (“SmCo”) magnets, the magnet class relied upon across U.S. military systems, by mid-2027, and confirmed it will respond to the U.S. Army’s sources sought notice for rare earth magnets.

    The portfolio — N42SH, N48SH, N46SH, N35SH, N45H, N42H, N48M and N50M — spans the medium-, high- and super-high-temperature classes that drive the bulk of global magnet demand. Seven of the eight grades have already completed customer certification, led by N42SH, the single largest grade in the global market at an estimated 23% of sintered NdFeB revenue, now in commercial production at EM&T’s operations in Pohang, South Korea. The eighth grade, N48SH, is in the final stages of customer certification. Market share figures are Company estimates.

    The portfolio’s revenue share exceeds its volume share by design: it is deliberately weighted toward the premium high-temperature grades that command the highest prices in the market. Its four super-high-temperature (“SH”) grades, rated to 150°C, incorporate heavy rare earths such as dysprosium and terbium to hold their magnetic strength under extreme heat, and alone are estimated to represent approximately 49% of global sintered NdFeB revenue on just 30% of volume. These are the grades specified for EV traction motors, wind turbine generators, aerospace generators and defense actuators — the most demanding, highest-value applications in the industry.

    With certification largely complete, EM&T’s priority for 2027 is scale. Thirteen additional ULVAC sintered magnet production machines are being delivered to Pohang, where the first 13 of 57 containers of ULVAC equipment have already arrived. The expansion is expected to lift annual capacity to more than 10,000 metric tons, including approximately 6,000 metric tons of high-performance sintered magnets, as the Company optimizes all eight grades for yield, consistency and throughput. On that foundation, EM&T reaffirms its fiscal 2026 revenue guidance of $10 million to $11 million and its fiscal 2027 revenue guidance of $400 million to $460 million.

    The planned SmCo line extends EM&T into the magnet class at the heart of U.S. defense systems. SmCo magnets retain their performance at temperatures beyond the reach of NdFeB and deliver superior corrosion resistance and thermal stability, making them the standard choice for guidance and control systems, aerospace actuators, and radar and satellite systems. The timing is deliberate. Effective January 1, 2027, DFARS 252.225-7052 extends its restriction on SmCo magnets across the entire supply chain, from ore through finished magnet, for qualifying U.S. defense deliveries, while samarium itself has been subject to China’s rare earth export licensing controls since April 2025. Demand for compliant, non-China SmCo supply is building now. The line will draw on the expertise of Kenji Konishi, EM&T’s Head of Magnet Engineering Production and former Vice President and Chief Technology Officer of JL MAG Rare Earth, whose background spans sintered NdFeB and SmCo magnet systems from alloy design through mass production.

    That demand is already surfacing at the federal level. On September 28, 2026, the U.S. Army Contracting Command, Aberdeen Proving Ground, Tobyhanna Division, issued a sources sought notice to identify potential vendors of rare earth magnets, with responses due October 28, 2026. EM&T will respond to the notice.

    “EM&T will be answering the U.S. Army’s call for rare earth magnets,” said Andrew Knaggs, President of EM&T. “In a highly unusual move, the U.S. Army appears to intend to acquire magnets directly for its defense apparatus and contractors. With seven customer-certified grades in production in Pohang and a SmCo line on the way, we believe EM&T is exactly the kind of supplier that requirement is looking for.”

    “Three quarters of the value in the global sintered magnet market sits in the eight grades EM&T produces, and our customers have already certified seven of them,” said David Wilcox, Executive Chairman of EM&T. “We did not build this portfolio around the edges of the market. We built it around the center, weighted toward the super-high-temperature grades that EV, wind, aerospace and defense customers specify and pay a premium for. 2027 is about execution: optimizing those eight grades as our new ULVAC capacity takes Pohang past 10,000 metric tons, and adding samarium cobalt, the magnet the U.S. defense industrial base depends on where heat and stability matter most. With DFARS reaching SmCo magnets on January 1, 2027 and samarium already under Chinese export licensing, demand for compliant supply is building now, and EM&T intends to meet it at commercial scale.”

    “We are growing, and the proof is on the ground in Pohang,” said Frank Moon, Chief Executive Officer of EM&T. “The first 13 of 57 containers of ULVAC equipment have arrived, seven of our eight grades carry customer certification, and our fiscal 2027 revenue guidance of $400 million to $460 million stands. These are not projections — they are milestones, and each one reflects production that is already scaling.”

    “The grades in this portfolio are the product of years of development in high-performance sintered magnets, a segment approximately ten times the size of the bonded magnet market,” said Kenji Konishi, Head of Magnet Engineering Production at EM&T. “That development is now in production. We are growing output of grades our customers have already certified, and our SmCo line will be built on the same engineering foundation.”

    About Evolution Metals & Technologies Corp.

    Evolution Metals & Technologies Corp. (Nasdaq: EMAT) is a U.S.-based critical materials and advanced manufacturing company for rare earth permanent magnets, battery materials, and related critical minerals and technologies. By leveraging proven commercial-scale operations, advanced processing technologies, and strategic partnerships, EM&T operates what it believes is the only vertically integrated critical materials supply chain spanning end-of-life electronics and batteries, high-grade concentrates, and the manufacture of finished rare earth magnets (including high-performance rare earth magnets) and battery materials. For additional information, please visit investors.evolution-metals.com and follow the Company on LinkedIn.

    Cautionary Note Regarding Forward-Looking Statements

    This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the Company’s fiscal 2026 revenue guidance of $10 million to $11 million and its fiscal 2027 revenue guidance of $400 million to $460 million and the assumptions underlying them; the completion and timing of customer certification of the Company’s N48SH grade; the Company’s estimates of the global market share represented by its sintered magnet grades; the Company’s plans to optimize production of its sintered magnet grades; the expected timing of the acquisition of equipment for, and the commencement of, samarium cobalt magnet production; the expansion of annual rare earth magnet production capacity in Pohang to more than 10,000 metric tons and the timing of delivery, installation and commissioning of ULVAC equipment; anticipated demand from defense, aerospace, automotive and industrial customers, including customers seeking DFARS-compliant supply; the January 1, 2027 effective date and scope of DFARS 252.225-7052; the Company’s intention to respond to the U.S. Army’s sources sought notice for rare earth magnets and any resulting procurement; and EM&T’s strategy, business plans and growth opportunities. These forward-looking statements, together with terms such as anticipate, expect, intend, may, will, should, believe, plan, positioned and other comparable terms, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Market share figures in this press release are Company estimates and may differ from actual market conditions. The Company’s guidance is based on management’s current expectations and assumptions, including anticipated customer demand, and is not based on contracted volumes. Such risks include, among others, customer qualification requirements and timing; whether the U.S. Army issues a solicitation or awards any contract; delays in equipment delivery, installation and commissioning; the Company’s ability to obtain working capital and other financing on acceptable terms, or at all, and to continue as a going concern; the availability and cost of non-China rare earth feedstock, including samarium; the Company’s ability to secure purchase orders from existing and prospective customers at anticipated volumes and prices; changes in the DFARS 252.225-7052 effective date, scope, waiver practices, tariffs or other government policies; competition; rare earth pricing and currency fluctuations; the Company’s ability to achieve contemplated production capacity, utilization levels, yields and operating efficiencies; financing, supply-chain and market risks; and the other risks described in EM&T’s filings with the U.S. Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results, performance or achievements may differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on these statements, which speak only as of the date made. EM&T undertakes no obligation to update any forward-looking statement except as required by law. Additional information concerning factors that may affect EM&T’s expectations and projections is contained in its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 20, 2026, its Quarterly Report on Form 10-Q for the three and six months ended June 30, 2026, filed with the SEC on August 17, 2026, including the disclosures under “Risk Factors” therein, and other documents filed or to be filed with the SEC by EM&T. SEC filings are available at www.sec.gov.

    Investor Relations Contacts

    Arx Investor Relations

    North American Equities Desk

    EMAT@arxhq.com

    Contact

    PR, Marketing & Global Partnerships:
    Phoenix MGMT & Consulting
    PR@PhoenixMGMTConsulting.com

  • Metrika Selected by OCC to Support Stablecoin Supervisory Framework Under the GENIUS Act

    Cambridge, MA, United States, October 14th, 2026, FinanceWire

    Federal contract awarded, effective August 17, 2026, covers stablecoin and digital asset payment expertise

    Metrika, Inc. has been awarded the Stablecoin Consultant Services contract by the Office of the Comptroller of the Currency (OCC), effective August 17, 2026.

    Under the award, Metrika will provide subject-matter expertise on stablecoin and digital asset payment activity in support of the OCC’s Business Unit establishing the supervisory framework to ensure compliance with the Guiding and Establishing National Innovation for U.S. Stablecoins (GENIUS) Act. The contract has a 6-month base period beginning August 17, 2026, with a 6-month option period, exercisable at the OCC’s discretion. The award was made via limited, i.e., other than full and open, competition and is publicly recorded on SAM.gov.

    “We’re grateful that Metrika’s expertise in digital asset risk has been recognized through this award,” said Nikos Andrikogiannopoulos, founder and CEO of Metrika. “Over the past several years, we have built technology and deep expertise at the intersection of digital asset infrastructure and institutional risk management, working with global systemically important banks, market infrastructure providers, asset managers, issuers, and credit rating agencies. Supporting the work of a U.S. prudential regulator is a significant extension of that journey, and we intend to meet the standard of rigor that comes with work of this kind.”

    “Throughout my career, I’ve seen periods when new technology changes financial infrastructure and, with it, how institutions and regulators need to think about risk,” said Hans Morris, Metrika board member and Managing Partner of Nyca Partners. “Stablecoins represent one of those transitions. Metrika has built a distinctive combination of technology, risk expertise, and experience working with major financial institutions.”

    About Metrika

    Metrika is a leading provider of risk management infrastructure for digital assets. Its platform enables financial institutions and regulatory organizations to identify, measure, and continuously monitor risks across stablecoins, tokenized assets, digital asset products, and the blockchain networks that support them.

    By combining deep digital asset expertise with institutional risk frameworks, Metrika transforms complex technical and operational data into measurable risk indicators, continuous monitoring, and actionable insights. Metrika works with global systemically important banks (G-SIBs), market infrastructure providers, asset issuers, asset managers, credit rating agencies, and regulatory bodies as they build, operate, and oversee digital asset activities.

    More information is available on Metrika’s website. https://www.metrika.co 

    Contact

    Renjie Butalid
    VP Business Development
    Metrika
    renjie@metrika.co

  • Metrika Selected by OCC to Support Stablecoin Supervisory Framework Under the GENIUS Act

    Cambridge, MA, United States, October 14th, 2026, FinanceWire

    Federal contract awarded, effective August 17, 2026, covers stablecoin and digital asset payment expertise

    Metrika, Inc. has been awarded the Stablecoin Consultant Services contract by the Office of the Comptroller of the Currency (OCC), effective August 17, 2026.

    Under the award, Metrika will provide subject-matter expertise on stablecoin and digital asset payment activity in support of the OCC’s Business Unit establishing the supervisory framework to ensure compliance with the Guiding and Establishing National Innovation for U.S. Stablecoins (GENIUS) Act. The contract has a 6-month base period beginning August 17, 2026, with a 6-month option period, exercisable at the OCC’s discretion. The award was made via limited, i.e., other than full and open, competition and is publicly recorded on SAM.gov.

    “We’re grateful that Metrika’s expertise in digital asset risk has been recognized through this award,” said Nikos Andrikogiannopoulos, founder and CEO of Metrika. “Over the past several years, we have built technology and deep expertise at the intersection of digital asset infrastructure and institutional risk management, working with global systemically important banks, market infrastructure providers, asset managers, issuers, and credit rating agencies. Supporting the work of a U.S. prudential regulator is a significant extension of that journey, and we intend to meet the standard of rigor that comes with work of this kind.”

    “Throughout my career, I’ve seen periods when new technology changes financial infrastructure and, with it, how institutions and regulators need to think about risk,” said Hans Morris, Metrika board member and Managing Partner of Nyca Partners. “Stablecoins represent one of those transitions. Metrika has built a distinctive combination of technology, risk expertise, and experience working with major financial institutions.”

    About Metrika

    Metrika is a leading provider of risk management infrastructure for digital assets. Its platform enables financial institutions and regulatory organizations to identify, measure, and continuously monitor risks across stablecoins, tokenized assets, digital asset products, and the blockchain networks that support them.

    By combining deep digital asset expertise with institutional risk frameworks, Metrika transforms complex technical and operational data into measurable risk indicators, continuous monitoring, and actionable insights. Metrika works with global systemically important banks (G-SIBs), market infrastructure providers, asset issuers, asset managers, credit rating agencies, and regulatory bodies as they build, operate, and oversee digital asset activities.

    More information is available on Metrika’s website. https://www.metrika.co 

    Contact

    Renjie Butalid
    VP Business Development
    Metrika
    renjie@metrika.co

  • Vantique Cleaners Highlights Detailed Rental Property Cleaning for Tenants Preparing to Move

    Australia, 14th Oct 2026 — Preparing a rental property for its final inspection can be a demanding part of moving, requiring tenants to manage packing, relocation arrangements, and household cleaning at the same time. Vantique Cleaners, an Australian residential cleaning company, provides professional cleaning services designed to help tenants and homeowners manage these responsibilities across Sydney, Melbourne, Perth, Brisbane, and surrounding suburbs.

    With a focus on detailed workmanship, customer satisfaction, and reliable service, Vantique Cleaners offers cleaning solutions for different property types and household requirements. Its services include end of lease cleaning, bond cleaning, regular house cleaning, carpet cleaning, tile and grout cleaning, window cleaning, pressure washing, driveway cleaning, and floor polishing.

    Making Rental Property Preparation More Manageable

    Moving out of a rental property often involves preparing multiple areas for inspection. Kitchens may require attention to grease and food residue, bathrooms can accumulate soap deposits and grime, and floors may need thorough cleaning after furniture has been removed. These tasks can become more time-consuming when tenants are working against a moving deadline.

    Professional bond cleaning services provide an option for tenants who want assistance with these detailed cleaning requirements. Vantique Cleaners approaches rental property cleaning with attention to the different areas that may require care before a property is handed back.

    A thorough cleaning process can help address everyday dirt and buildup that develops during a tenancy. Depending on the property’s condition and agreed service requirements, customers may seek cleaning for kitchens, bathrooms, living areas, floors, and other household spaces.

    By arranging professional assistance, tenants can organize their moving schedules while leaving cleaning tasks to an experienced team.

    Understanding the Importance of Bond Back Cleaning

    Bond back cleaning is commonly associated with preparing a rental property for its final inspection. The process focuses on leaving the premises clean and addressing areas that may have accumulated dirt during everyday use.

    For people searching for bond back cleaning, understanding the scope of the service is an important first step. Cleaning requirements can differ depending on the rental agreement, the property’s condition, and applicable tenancy rules. Establishing which areas need attention before booking can help customers select an appropriate service.

    Vantique Cleaners provides bond back cleaners for customers seeking professional support during the move-out process. Its cleaning services are intended to help prepare residential properties for handover through detailed attention to household surfaces and frequently used spaces.

    Although professional cleaning can support rental property preparation, a bond refund is not guaranteed by cleaning alone. Final outcomes may depend on inspection findings, the tenancy agreement, and the relevant local regulations.

    Cleaning Options Beyond the Final Inspection

    Although rental property preparation is an important reason to arrange a professional clean, residential cleaning needs extend beyond moving day. Regular maintenance can help households keep their living spaces comfortable, while specialized services can address surfaces that need additional attention.

    Vantique Cleaners offers regular house cleaning for ongoing household upkeep, along with carpet cleaning, tile and grout cleaning, and window cleaning. For outdoor areas, its services include pressure washing and driveway cleaning. Floor polishing is also available for customers seeking additional care for suitable flooring surfaces.

    These options allow customers to consider different cleaning requirements according to their property’s needs. Someone preparing to vacate a rental home may require a detailed end of lease clean, while another household may be looking for periodic assistance with routine maintenance.

    The availability of multiple services through one provider can also simplify the process of arranging cleaning for different areas of a property.

    Customers can review the company’s dedicated service information at https://vantiquecleaners.com.au/bond-back-cleaning/.

    A Service Approach Built Around Experience and Attention to Detail

    Vantique Cleaners reports serving more than 1,200 satisfied clients, completing over 8,000 cleans, and working with a team of more than 50 cleaners. The company operates across several major Australian cities, including Sydney, Melbourne, Perth, and Brisbane, as well as surrounding suburbs.

    Its approach combines experienced cleaning personnel, professional-grade equipment, and eco-friendly cleaning products. These elements support its focus on providing consistent cleaning services for homes and rental properties.

    Attention to detail is particularly relevant when preparing a property for handover, as different rooms and surfaces can require different cleaning methods. Customers can discuss their needs with the company to understand the available services and determine which option is appropriate for their property.

    Helping Customers Plan Their Next Move

    Organizing a move involves coordinating numerous responsibilities, from arranging transportation to ensuring that a property is ready for its next occupants. Professional cleaning can help reduce the amount of work tenants need to manage independently during this transition.

    Vantique Cleaners provides bond cleaning, bond back cleaning services, and other residential cleaning options for customers seeking support with property maintenance and moving preparations. Its service coverage across major Australian cities gives households in these locations an opportunity to explore professional assistance suited to their needs.

    Customers interested in booking a cleaning service or learning more about available options can contact Vantique Cleaners directly.

    About Vantique Cleaners

    Vantique Cleaners is an Australian cleaning company providing residential, rental property, and move-out cleaning services. Its offerings include bond cleaning, end of lease cleaning, regular house cleaning, carpet cleaning, tile and grout cleaning, window cleaning, pressure washing, driveway cleaning, and floor polishing.

    Media Contact:
    Vantique Cleaners
    Phone: 1300 070 945
    Email: contact@vantiquecleaners.com.au
    Website: https://vantiquecleaners.com.au/

    Media Contact

    Organization: Vantique Cleaners

    Contact Person: Support Team

    Website: https://vantiquecleaners.com.au/

    Email: Send Email

    Country: Australia

    Release id: 49913

    View source version on King Newswire:
    Vantique Cleaners Highlights Detailed Rental Property Cleaning for Tenants Preparing to Move

    file

  • Maintaining Property Value Through Specialized Cleaning: Vantique Cleaners Offers Solutions Across Australia

    Australia, 14th Oct 2026 – Keeping a property in good condition requires consistent attention to surfaces, flooring, windows, and other areas that experience regular use. For landlords, property managers, homeowners, and tenants, professional cleaning can form part of a broader approach to property care. Vantique Cleaners provides a range of residential cleaning services designed to support these needs across Sydney, Melbourne, Perth, Brisbane, and surrounding suburbs.

    From routine house cleaning to specialized floor and carpet care, the company offers services suited to different property types and cleaning requirements. Its approach combines experienced cleaners, professional-grade equipment, and eco-friendly cleaning products to help customers maintain clean and comfortable environments.

    A Broader Approach to Residential Property Care

    Regular cleaning helps address the everyday buildup of dust, dirt, and grime that can affect the appearance of frequently used spaces. However, some areas require more specialized attention than standard household maintenance provides.

    Carpets, tiled surfaces, grout lines, windows, and outdoor driveways can present different cleaning challenges. Vantique Cleaners offers services covering these areas, including carpet cleaning, tile and grout cleaning, window cleaning, pressure washing, driveway cleaning, and floor polishing.

    By offering multiple cleaning options, the company enables customers to consider the specific needs of their properties and identify appropriate services. Homeowners may require periodic deep cleaning, while landlords and property managers may need support preparing a property for new occupants.

    Specialized Cleaning for Rental Properties

    Rental properties experience changing cleaning requirements as tenants move in and out. Preparing a property for a new occupant may involve addressing accumulated dirt, cleaning high-use areas, and ensuring that different surfaces receive appropriate attention.

    Professional end of lease cleaning provides an option for tenants and property owners seeking assistance with this process. A detailed cleaning plan can help address kitchens, bathrooms, floors, and other areas that may need attention before a property handover.

    The scope of professional end of lease cleaning services can vary according to the property’s size, condition, and agreed service package. Customers should confirm which tasks are included and review any specific requirements established by their rental agreement or property manager.

    For landlords, maintaining consistent cleaning standards between tenancies can support a more organized property management process. For tenants, arranging cleaning before moving day can help them manage one of the many responsibilities associated with relocating.

    Giving Carpets, Tiles, and Floors Appropriate Attention

    Different flooring materials require different cleaning approaches. Carpets can collect dust and everyday debris, while tile surfaces and grout lines may develop visible dirt over time. Hard floors can also benefit from appropriate cleaning and maintenance.

    Vantique Cleaners offers carpet cleaning and tile and grout cleaning alongside its wider residential services. Customers preparing to vacate a rental property can explore end of lease cleaning services to learn more about cleaning options relevant to their circumstances.

    Where additional carpet care is needed, customers can ask about end of lease carpet cleaning and whether it is included in their selected package or arranged as a separate service.

    Understanding the property’s flooring materials and condition before booking can help customers communicate their needs and establish realistic expectations for the cleaning work.

    Selecting Services According to Property Needs

    Not every property requires the same cleaning schedule or combination of services. An apartment may need attention to its kitchen, bathroom, windows, and flooring, while a larger house may require a broader cleaning plan. Outdoor areas, including driveways, may also need periodic cleaning depending on their condition and use.

    Vantique Cleaners offers regular house cleaning, bond back cleaning, window cleaning, pressure washing, driveway cleaning, and floor polishing, allowing customers to explore services according to their requirements.

    Customers can also request end of lease cleaning quotes to understand the potential cost of preparing a property. Pricing may depend on the size of the property, its current condition, the number of rooms, and any additional tasks requested.

    Providing accurate property details when requesting a quote can help clarify the proposed scope of work. Customers should also ask about appointment availability if cleaning must be completed within a particular timeframe.

    An Established Cleaning Service Across Major Australian Cities

    Vantique Cleaners reports serving more than 1,200 satisfied clients, employing over 50 cleaners, and completing more than 8,000 cleans. The company serves customers across Sydney, Melbourne, Perth, Brisbane, and surrounding suburbs.

    Its combination of general and specialized cleaning services provides an option for customers seeking assistance with ongoing property maintenance or more detailed cleaning projects. By discussing their priorities and confirming the services available for their location, customers can plan cleaning arrangements around their property requirements.

    For more information about residential cleaning options, visit the Vantique Cleaners website. Customers preparing a rental property for handover can also explore the company’s dedicated end of lease cleaning page.

    About Vantique Cleaners

    Vantique Cleaners is an Australian cleaning company providing services for homes, rental properties, and customers preparing to move. Its services include regular house cleaning, end of lease cleaning, bond back cleaning, carpet cleaning, tile and grout cleaning, window cleaning, pressure washing, driveway cleaning, and floor polishing.

    Media Contact:
    Vantique Cleaners
    Phone: 1300 070 945
    Email: contact@vantiquecleaners.com.au
    Website: https://vantiquecleaners.com.au/

    Media Contact

    Organization: Vantique Cleaners

    Contact Person: Support Team

    Website: https://vantiquecleaners.com.au/

    Email: Send Email

    Country: Australia

    Release id: 49914

    View source version on King Newswire:
    Maintaining Property Value Through Specialized Cleaning: Vantique Cleaners Offers Solutions Across Australia

    file